JP-7857437-B2 - Probiotic complex composition having immunomodulatory and immunohomeostatic functions

Inventors

• ソン，ミン
• パク，ゼ ソン
• シン，ソ リム
• ユ，イェ ジ

Assignees

• ラクトメイソン カンパニー リミテッド

Dates

Publication Date

20260512

Application Date

20220830

Priority Date

20220526

Claims (3)

1. A composition for maintaining immune homeostasis by increasing or suppressing NO production, comprising a mixed strain containing Lactobacillus reuteri LM1071 strain (KCCM12650P) and Lactobacillus plantarum LM1001 strain (KCCM42959) as an active ingredient, The aforementioned mixed strains consist of Lactobacillus reuteri LM1071 strain (KCCM12650P) and Lactobacillus plantarum LM1001 strain (KCCM42959) in a ratio of 8:1 to 1:4. A composition for maintaining immune homeostasis by increasing or suppressing NO production .
2. A food composition for maintaining immune homeostasis, comprising the composition for maintaining immune homeostasis described in claim 1 as an active ingredient, through increasing or suppressing NO production .
3. A health functional food composition for maintaining immune homeostasis, comprising the composition for maintaining immune homeostasis described in claim 1 as an active ingredient, through increasing or suppressing NO production .

Description

K.C.C.M. KCCM12650P K.C.C.M. KCCM 42959 K.C.C.M. KCCM 43246 K.C.C.M. KCCM 80146 K.C.C.M. KCCM12919P K.C.C.M. KCCM12629P K.C.C.M. KFCC11771P This application relates to a mixed strain of probiotics having immunomodulatory functions, and a composition containing the same. The human digestive tract is home to a vast number of bacteria. While the human body contains approximately 10 trillion normal cells, the number of bacteria is about 10 times greater, around 100 trillion. The majority of these bacteria form the gut microbiota and influence the body's immune regulation through interactions with various bacteria present in the intestines. These bacteria can be divided into beneficial bacteria that contribute to human gut health and harmful bacteria that are detrimental to health. The human body maintains health when beneficial bacteria are dominant over harmful bacteria such as E. coli, Veillonella, and Clostridium perfringens, and when a balance is maintained among the various microorganisms residing in the digestive tract. Human body necrotic cells maintain health by controlling invading antigens (including microorganisms) and internally occurring abnormal cells. More than 70% of these necrotic cells are located in the digestive tract, controlling microorganisms already residing in the tract or those invading from the outside. However, excessive activation of the immune response by these necrotic cells can induce diseases such as allergies, rheumatism, atopic dermatitis, asthma, rheumatoid arthritis, lupus, inflammatory bowel disease (ulcerative colitis, Crohn's disease, diverticulosis, etc.), and diabetes. Therefore, immunomodulatory ability to suppress excessively activated immune responses and maintain immune homeostasis plays a crucial physiological role in the immune system's prevention of the above-mentioned diseases. Among necrotic cells, T cells can directly eliminate host cells infected with bacteria or viruses, and helper T cells, in particular, promote the differentiation and activation of other necrotic cells (cellular and humoral immune responses). Such activated immune responses are suppressed by regulatory T cells (Tregs), which are known to play a crucial role in maintaining immune homeostasis. Intestinal bacteria, while acting as antigens and triggering immune responses in the human body, also possess mechanisms of immune tolerance to reduce these responses in order to coexist with the body. Some of these mechanisms are known to be involved in the differentiation process of T cells, inducing the differentiation and proliferation of regulatory T cells in the gut. Examples of compositions developed using such microorganisms for immunomodulation include novel lactic acid bacteria derived from the human gastrointestinal tract with immunomodulatory effects and their applications (Korean Patent Registration No. 10-1862051). However, in-depth development and diverse research on compositions exhibiting superior effects related to immunomodulation remain necessary. Therefore, the inventors of this invention have made diligent efforts to develop a composition with excellent immunomodulatory function. As a result, they have developed a mixed bacterial strain and a composition containing it that can regulate immunity by increasing NO production or suppressing excessive NO production induced by inflammatory substances, thereby achieving the present invention. Korean Registered Patent No. 10-2224027 This figure shows the amount of NO produced (confirmation of immunostimulatory ability) when (a) LM1071 strain and (b) LM1001 strain are treated individually, according to one embodiment of the present invention.This figure shows the suppression of NO production induced by LPS (confirmation of anti-inflammatory activity) when (a) LM1071 strain and (b) LM1001 strain are treated individually, according to one embodiment of the present invention.This figure shows the amount of NO produced by the LM1071 strain and the LM1001 strain according to one embodiment of the present invention ((a) confirmation of immune-enhancing ability) and the suppression of NO production induced by LPS ((b) confirmation of anti-inflammatory ability).This figure shows the amount of NO produced (confirmation of immune-enhancing ability) by five bacterial strains ((a) LM1009, (b) LM1012, (c) LM1017, (d) LM1024, (e) dead cells of LM1004) in one embodiment of the present invention.This figure shows the suppression of NO production induced by LPS (confirmation of anti-inflammatory activity) when five bacterial strains ((a) LM1009, (b) LM1012, (c) LM1017, (d) LM1024, (e) dead cells of LM1004) related to one embodiment of the present invention are treated individually.This figure shows the amount of NO produced by a mixture of seven bacterial strains according to one embod